Anti-Human CD11A Recombinant Antibody (TAB-024) (CAT#: TAB-024)

Recombinant monoclonal antibody to Human CD11A. It is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. It binds to the CD11a subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. It was associated with fatal brain infections and was withdrawn from the market in 2009.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Formats:
  • Isotype Switching:
  • Fc Engineering:
  • Modalities:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • Neut, ELISA, IF, IP, FuncS, FC, WB, Inhib
  • Related Disease
  • Psoriasis (infection in chronic moderate to severe plaque)

Product Property

  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The ITGAL antibody has been reported in applications of Neut, ELISA, IF, IP, FuncS, FC, WB, Inhib.

Target

  • Alternative Names
  • Efalizumab;raptiva;214745-43-4;hu1124;DB00095ITGAL;integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1;alpha polypeptide);CD11A;integrin alpha-L;LFA 1;LFA-1A;LFA-1 alpha;integrin gene promoter;CD11 antigen-like family member

Related Resources

  • Biosimilar Overview
Please refer to Efalizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Efalizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "ITGAL"

Select a product category from the dropdown menu below to view related products.
Please select product type
Mouse Antibody Products Fab Antibody Products ScFv Antibody Products Chimeric Antibody Products Neutralizing Antibody Products Blocking Antibody Products Rabbit Monoclonal Antibody Products IgG Antibody Products Neuroscience Antibody Products ADCC Enhanced Antibody Products Single Domain Antibody Products

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-024. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare